丙卡特罗联合布地奈德治疗儿童咳嗽变异性哮喘作用研究  

Study on procaterol combined with budesonide for the treatment of pediatric cough-variant asthma

作　　者：鱼湘 陈海英 丁彩霞[3] 

机构地区：[1]陕西省西安市东郊第一职工医院儿科,710043 [2]陕西省榆林市儿童医院重症医学科 [3]陕西省榆林市第二医院重症医学科

出　　处：《山西医药杂志》2015年第21期2476-2479,共4页Shanxi Medical Journal

摘　　要：目的研究丙卡特罗联合布地奈德治疗儿童咳嗽变异性哮喘的效果和安全性。方法开展前瞻性、随机双盲、安慰对照实验,163例咳嗽变异性哮喘患者（年龄2-10岁）按随机数字表法分为2组,吸入布地奈德20μg并口服丙卡特罗8μg或者安慰剂,每天2次,共计8周。咳嗽症状严重程度评分和莱斯特咳嗽问卷（LCQ）生活质量评分作为主要的和次要的疗效衡量标准,同时对于治疗期间的不良反应进行评估。结果布地奈德、安慰剂组和布地奈德、丙卡特罗组患者例数分别为81例和80例（2例患者因为其后期被诊断为细胞性支气管炎而被排除）,2组患者基本特征类似。治疗期间2组的日咳嗽分数均降低,且后者分数更低,8周（0.42与0.75）和10周（0.32与0.61）,差异有统计学意义（P〈0.05）。与布地奈德、安慰剂组比较,布地奈德、丙卡特罗组日咳嗽分数降低3分或3分以上的患者比例（67%与42%）和获0分的患者比例（64与52%）更高,差异有统计学意义（P〈0.05）;8周时,布地奈德、丙卡特罗组LCQ生活质量分数提高的更多,41±18与33±18;差异有统计学意义（P〈0.05）。结论口服丙卡特罗联合吸入布地奈德的治疗方法可以改善儿童咳嗽变异性哮喘患者症状,改善其生活质量,且耐受性良好。Objective We evaluated the efficacy and safety of procaterol combined with budesonide for cough-variant asthma（CVA）.Methods A prospective,randomized,double-blind,and placebo-controlled study was conducted.One hundred and sixty-three patients diagnosed with CVA（aged 2-10years）were randomly divided into two groups to receive twice daily for 8weeks,inhaled budesonide 20 mg plus either oral procaterol 8mg or placebo.Primary and secondary efficacy variables were cough symptom severity scores and Leicester Cough Questionnaire（LCQ）life quality scores.And we also assessed the adverse events.Results The budesonide/placebo and budesonide/procaterol groups contained 81 and 80participants（two patients excluded for later diagnosis of eosinophilic bronchitis）,with similar baseline characteristics,respectively.Daily cough score decreased during treatment in both groups and was lower in the budesonide/procaterol group at 8and 10weeks（0.42 vs 0.75,0.32 vs0.61,P〈0.05）.The proportion of patients with a reduction of 3points or greater and that of patients scored zero points was higher in the budesonide/procaterol group for daily cough scores（67%vs 42%,64%vs 52%,P〈0.05）,compared with the budesonide/placebo group.At 8 weeks,LCQ score improvement was greater in the budesonide/procaterol group（41±18 vs 33±18,P〈0.05）.Conclusion Oral administration procaterol combined with inhaled budesonide was a well-tolerated and effective method of improving cough symptoms and enhancing the quality of CVA patients′life.

关 键 词：丙卡特罗 咳嗽变异性哮喘 哮喘 糖皮质激素 Β2肾上腺素受体激动剂 

分 类 号：R725.6[医药卫生—儿科]